Don't Forget To
Rate This Article

Get the Latest Investment Ideas Delivered Straight to Your Inbox. Subscribe


BioNTech and Pfizer Secure $3.2B Vaccine Order from US Govt.
Trending Company

Share on Stocktwits


Shares of BioNTech SE traded 5% higher after the company together with its partner Pfizer Inc. reported that the two firms have agreed to provide 105 million 30 g, 10 g and 3 g new doses of the SARS-Co-V2 vaccine to the U.S. government in a contract valued at $3.2 billion. The agreement includes a provision allowing the U.S. government to purchase up to an additional 195 million doses, which if exercised would increase the grand total to 300 million doses.

Yesterday afternoon, leading global mRNA-based vaccine developers BioNTech SE (BNTX:NASDAQ) and Pfizer Inc. (PFE:NYSE) announced that the two companies had entered into a new vaccine supply agreement with the U.S. government to support ongoing efforts in combatting COVID-19.

Under the terms of the agreement, BioNTech and Pfizer will be tasked with supplying the U.S. government with 105 million additional COVID-19 doses in various strengths (30 µg, 10 µg and 3 µg) starting in late summer and ti be completed by the end of Q4/22 for a delivered price of $3.2 billion.

The firms noted that predicated upon receipt of authorization from the U.S. Food and Drug Administration (FDA), it is possible that these vaccines may include adult Omicron-adapted COVID-19 vaccines.

The agreement stipulates that the U.S. government will have the option to purchase up to 195 million additional doses, which if it elected would bring the total number of ordered doses to 300 million.

Pfizer's Chairman and CEO Albert Bourla commented, "As the virus evolves, this new agreement will help ensure people across the country have access to vaccines that may provide protection against current and future variants…Vaccines have been and will remain critical to protecting people of all ages against COVID-19. We remain proud of our long-term partnership with the U.S. government in helping to address this pandemic, and of the ongoing impact of vaccination efforts in the U.S. and around the world."

BioNTech's Chief Business and Chief Commercial Officer Sean Marett stated, "This agreement will provide additional doses for U.S. residents and help cope with the next COVID-19 wave. Pending regulatory authorization, it will also include an Omicron-adapted vaccine, which we believe is important to address the rapidly spreading Omicron variant…We appreciate the continued partnership of the U.S. government in our shared goal to help end this pandemic."

The report indicated that the two companies released "pivotal data demonstrating the safety, tolerability and immunogenicity of two Omicron-adapted vaccine candidates" on June 25, 2022. The firms advised that the data was submitted to the FDA and other regulators and indicated that a request for U.S. Emergency Use Authorization is expected to be filed.

In the meantime, the companies stated that they have commenced manufacturing the newer Omicron-adapted vaccine candidates at their own risk in anticipation of a positive response from the FDA and as to be ready to ship as soon as possible upon approvals by the FDA and by the U.S. Centers for Disease Control and Prevention (CDC).

The companies stated that once all necessary authorizations are obtained, "eligible U.S. residents will continue to receive the vaccine for free, consistent with the U.S. government's commitment for free access to COVID-19 vaccines."

The Pfizer-BioNTech COVID-19 vaccine was jointly developed using BioNTech's proprietary messenger ribonucleic acid (mRNA) technology. The report pointed out that "BioNTech is the Marketing Authorization Holder in the U.S., the EU, the U.K., Canada and other countries, and the holder of emergency use authorizations or equivalents in the U.S. (jointly with Pfizer) and other countries."

BioNTech is based in Mainz, Germany. The company is focused on providing next generation immunotherapies for cancer and other serious diseases. The firm stated that "its broad portfolio of oncology product candidates includes individualized and off-the-shelf mRNA-based therapies, innovative chimeric antigen receptor T cells, bi-specific checkpoint immuno-modulators, targeted cancer antibodies and small molecules."

Pfizer is a global biopharma company headquartered in New York, N.Y. The firm is engaged in the discovery, development, and manufacture of pharmaceuticals and healthcare products. Pfizer's global brand portfolio includes many well-known medications including Celebrex, Eliquis, Lipitor, Prevnar 13, Viagra and Xeljanz. The firm's shares trade on the NYSE and it has a market cap of around $286 billion.

BioNTech started the day with a market cap of around $34.5 billion with approximately 243.0 million shares outstanding. BNTX shares opened more than 3% higher today at $146.525 (+$4.545, +3.20%) over yesterday's $141.98 closing price. The stock traded today between $142.10 and $153.80 per share and closed for trading at $149.10 (+$7.12, +5.01%).

Want to be the first to know about interesting Biotechnology / Pharmaceuticals investment ideas? Sign up to receive the FREE Streetwise Reports' newsletter. Subscribe

1) Stephen Hytha compiled this article for Streetwise Reports LLC and provides services to Streetwise Reports as an independent contractor. He or members of his household own securities of the following companies mentioned in the article: None. He or members of his household are paid by the following companies mentioned in this article: None.
2) The following companies mentioned in this article are billboard sponsors of Streetwise Reports: None. Click here for important disclosures about sponsor fees.
3) Comments and opinions expressed are those of the specific experts and not of Streetwise Reports or its officers. The information provided above is for informational purposes only and is not a recommendation to buy or sell any security.
4) The article does not constitute investment advice. Each reader is encouraged to consult with his or her individual financial professional and any action a reader takes as a result of information presented here is his or her own responsibility. By opening this page, each reader accepts and agrees to Streetwise Reports' terms of use and full legal disclaimer. This article is not a solicitation for investment. Streetwise Reports does not render general or specific investment advice and the information on Streetwise Reports should not be considered a recommendation to buy or sell any security. Streetwise Reports does not endorse or recommend the business, products, services or securities of any company mentioned on Streetwise Reports.
5) From time to time, Streetwise Reports LLC and its directors, officers, employees or members of their families, as well as persons interviewed for articles and interviews on the site, may have a long or short position in securities mentioned. Directors, officers, employees or members of their immediate families are prohibited from making purchases and/or sales of those securities in the open market or otherwise from the time of the decision to publish an article until three business days after the publication of the article. The foregoing prohibition does not apply to articles that in substance only restate previously published company releases.
6) This article does not constitute medical advice. Officers, employees and contributors to Streetwise Reports are not licensed medical professionals. Readers should always contact their healthcare professionals for medical advice.

Want to read more about Biotechnology / Pharmaceuticals investment ideas?
Get Our Streetwise Reports Newsletter Free and be the first to know!

A valid email address is required to subscribe